

## Course Detail

**MMWR Weekly – December 9, 2011**

**Course Number: SS1747-12092011**

**CE Origination Date: December 9, 2011**

**CE Expiration Date: January 23, 2012**

## Content Experts/Prepares

### **State-Specific Prevalence of No Leisure-Time Physical Activity Among Adults With and Without Doctor-Diagnosed Arthritis — United States, 2009**

Kamil E. Barbour, PhD, EIS Officer, CDC

Carmen Harris, MPH, Epidemiologist, Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, CDC

Jennifer M. Hootman, PhD, Epidemiologist, Arthritis Program, Division of Adult and Community Health, Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, CDC

Kathleen B. Watson, PhD, Epidemiologist, Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, CDC

### **Recommendations for Use of an Isoniazid–Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection**

Stefan V. Goldberg, MD, Medical Officer, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC

John A. Jereb, MD, Medical Officer, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC

Philip LoBue, MD, Associate Director for Science, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC

Krista Powell, MD, Medical Officer, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC

M. Elsa Villarino, MD, Medical Officer, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC

## Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: N/A